Time filter

Source Type

SUNNYVALE, CA, United States

Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 224.99K | Year: 2014

DESCRIPTION (provided by applicant): Tumor-induced osteomalacia (TIO, or oncogenic osteomalacia) is an insidious, progressive, paraneoplastic disorder of abnormal phosphate and vitamin D metabolism caused by excessive fibroblast growth factor 23 (FGF23).Due to a lack of appreciation of the existence of this disease, as well as a typically slow onset of symptoms, the prevalence of TIO is most likely under-estimated. Chronically elevated FGF23 leads to renal phosphate wasting with resultant hypophosphatemiaand phosphaturia, low vitamin D, and osteomalacia, with frequent fractures. Elevated FGF23 may also lead to a) secondary hyperparathyroidism (SHPT), b) renal osteodystrophy, c) extra-skeletal calcification, and d) left ventricular hypertrophy (Tomasello,2008). Proteolytic cleavage of FGF23 produces a C-terminal peptide (FGF23c) that acts as an endogenous inhibitor of the fulllength, bioactive form of FGF23 to alleviate FGF23-mediated renal phosphate wasting (Goetz, 2010). To develop a best-in-class t

Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 306.52K | Year: 2014

Abstract Novel Hybrid Growth Factor for Immune Reconstitution in Sepsis Sepsis is a major clinical problem with more than a 40% mortality rate, and is the leading cause of death in intensive care units. Despite a great deal of investment of time and moneyin basic and clinical research including more than 40 clinical trials, there is no FDA-approved drug for sepsis. Historically, experimental sepsis treatments focused on the early phase which consists of a systemic inflammatory response syndrome (SIRS) characterized by excessive production of pro-inflammatory mediators by immune cells. Although experimental treatment modalities targeting inflammatory mediators (e.g. TNF-a or IL-1) were often effective in animal models, they failed in human clinical trials.It is now understood that following the early acute phase, there is a transition to a compensatory anti-inflammatory response syndrome (CARS) to limit damage, leading to immunosuppression and promotion of chronic infection . In the chronic phase of sepsis

Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase II | Award Amount: 955.59K | Year: 2015

DESCRIPTION provided by applicant Antibody Membrane Switch AMS technology for optimized antibody engineering Abstract Generation of high productivity cell lines remains a major bottleneck in therapeutic antibody development Conventional cell line development depends on gene amplification methodologies using dihydrofolate reductase DHFR or glutamine synthetase GS Higher productivity is associated with an increased gene copy number However lack of selection pressure under the conditions of large scale manufacturing leads to clonal instability We have developed a novel method for cell line development Antibody Membrane Switch AMS technology that does not rely on gene amplification This FACS based high throughput method is facilitated by cell surface antibody expression to rapidly and efficiently isolate high producing cells The switch between membrane expression and secretion is achieved by alternative splicing and specific DNA recombination The antibody of interest is initially displayed on the cell surface to facilitate FACS Isolated high producing cells are then seamlessly transformed into production cells after removing the membrane anchoring domain sequence via a DNA recombinase AMS technology has been applied in a number of antibody cell line development projects which typically last months The top manufacturing cell lines exhibit very high specific productivity of pg cell day resulting in production titers of g L in day batch culture In Phase I studies the underlying AMS methods were reduce to practice Furthermore we have optimized the AMS process using two biosimilar antibodies In Phase II these optimized methods will be applied to screening of CHO surface displayed antibody libraries An affinity maturation library and a na ve human antibody library will be constructed and utilized to screen by FACS for therapeutic antibody candidates The screening will be carried out with soluble antigen for high affinity binding or antigen e g GPCR presenting cells for desired bio activities The isolated positive cells will be transformed into antibody production cells by DNA recombinase to remove the membrane anchorage This successful application of AMS technology will permit the discovery of antibodies to be seamlessly linked to downstream cell line development providing the basis for rapid facile cell line production directly from a novel antibody discovery platform Phase I R AI A PUBLIC HEALTH RELEVANCE Therapeutic antibodies are expensive in part due to the costly time consuming steps involved in the development of stable high expressing cell lines for production We describe a novel cell line development method that utilizes alternative splicing of a membrane anchored Fc domain and fluorescence activated cell sorting FACS to rapidly identify antibody production cell lines with greatly reduced time and cost The same platform will be optimized to screen affinity maturation or synthetic antibody libraries and thereby facilitating seamless transformation into production cell lines

Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 224.62K | Year: 2015

DESCRIPTION provided by applicant Novel NMDA Receptor Antagonists for Beta Cell Rescue Abstract Type diabetes mellitus T DM is rapidly becoming the most common chronic disease in the US with more than of the adult population affected and million new cases per year Fundamentally T DM involves beta cell dysfunction and poor control of blood glucose levels resulting in hyperglycemia Impaired insulin secretion is accompanied by a decrease in beta cell mass an increase in apoptosis of beta cells and a reduced functional capacity of the remaining cells A disease modifying treatment would not only promote insulin secretion but also reduce apoptosis and increase proliferation of beta cells Recent data from animal models and Phase clinical studies in humans suggest that NMDA receptors NMDAR inhibit insulin release and promote beta cell death and that NMDAR antagonists act as insulin secretagogues and can increase beta cell mass Although further mechanistic studies are required to fully understand the function of NMDARs in beta cells NMDARs may act as part of a negative feedback loop in pancreatic islets to ensure that insulin is not released in an excessive manner at high blood glucose concentrations The lack of extreme blood glucose lowering effects with high dose and long term exposure to NMDAR antagonists suggests that such treatment is unlikely to lead to life threatening hypoglycemia such as is seen with sulfonylurea treatment The larger islet cell mass observed in diabetic mice upon long term treatment with a high dose versus a low dose of NMDAR antagonists also indicates that inhibition of NMDARs could maintain the number of beta cells in diabetes These data suggest that NMDAR antagonists may be useful to reduce or even reverse progression of human diabetes Memantine an aminoadamantane selectively inhibits abnormally active NMDAR channels while preserving normal activity and physiological neuronal function Memantine has been approved for the treatment of moderate to severe Alzheimerandapos s disease for over years Pathological NMDA receptor activity is further down regulated by S nitrosylation of specific cysteine residues Taking advantage of these insights PRI has developed a proprietary series of bifunctional antagonists called nitromemantines that not only preferentially bind to the open channel state but also selectively target NO to a second modulatory site on the NMDAR using the memantine pharmacophore as a homing motif During this Phase I study we will evaluate our lead nitromemantine YQW for its activity in vitro and in an animal model of T DM Successful achievement of these milestones will provide a proprietary first in class disease modifying drug for T DM PUBLIC HEALTH RELEVANCE Type diabetes mellitus T DM affects over million people worldwide and its incidence is increasing T DM is associated with an increased risk of disease of the eye kidney and cardiovascular system Current treatments do not alter the long term course of the disease We have developed a new class of drugs that bind to a receptor that is critical for normal function and maintenance of normal numbers of pancreatic beta cells the cells that secrete insulin We will evaluate these new compounds as potential treatments for T DM

Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 223.80K | Year: 2015

DESCRIPTION provided by applicant Idiopathic pulmonary fibrosis IPF is a chronic fatal lung disease characterized by rapid progressive loss of pulmonary function IPF is a major health problem as it affects more than typically middle aged people in the USA Quality of life rapidly deteriorates due to dyspnea and IPF associated symptoms such as pulmonary hypertension and heart failure The year mortality rate for IPF is greater than many malignancies including bladder cancer colon cancer and multiple myeloma A major need exists for effective therapeutics IPF is characterized by increased collagen deposition fibrosis by an excessive number of myofibroblasts in the lung interstitium Inappropriate proliferation and function of fibroblasts alveolar epithelial cells and embedded mesenchymal stem cells play key roles in the pathogenesis of the disease Although the molecular mechanisms that underlie this idiopathic disease have been obscure recent progress has been made Of key importance has been the identification of Wnt signaling as necessary for fibrosis in a wide variety of fibrotic diseases including IPF This is consistent with Wnt signaling playing a key regulatory role in normal wound healing tissue repair and regeneration fibrotic disease in the lung results from aberrant repair regeneration in which alveolar type AT epithelial progenitor cells stop functioning midway through repair Attenuation of Wnt signaling decreases pulmonary fibrosis in several mouse models of IPF A unifying treatment hypothesis for fibrotic disease suggests that attenuating pathologically high levels of Wnt signaling but preserving sufficient signaling will allow repair to resume We have developed a biologically active monoclonal Ab mAb that binds to the E E domains of Wnt co receptor LRP to reduce Wnt signaling by direct competition The mAb also downregulates LRP expression through endocytosis Our anti LRP mAb likely works in part by competing with the pro fibrotic Wnts that activate canonical Wnt signaling and decreasing the ability of LRP to act as a co receptor for PDGF BB CTGF and TGF mediated signaling This mAb is expected to be biologically active in a wide range of conditions it has already been shown to exert significant biological activity in mouse models of diabetic retinopathy and choroidal neovascularization We have constructed humanized versions of this mAb that bind LRP to attenuate Wnt signaling We propose to demonstrate that a humanized anti LRP mAb will sufficiently antagonize Wnt signaling in pulmonary fibrosis to inhibit progression of fibrosis of IPF and restore the cellular and extracellular milieu to permit homeostatic repair Our anti LRP humAb is postulated to be a first in class rationally designed therapy to reduce fibrosis in IPF and may be useful in other fibrotic diseases affecting the skin liver and kidney associated with aberrant Wnt signaling PUBLIC HEALTH RELEVANCE Idiopathic pulmonary fibrosis IPF is a devastating progressive and ultimately fatal lung disease We have created a rationally targeted antibody as a potential therapeutic for IPF

Discover hidden collaborations